This phase 3 study is testing a new contraceptive patch (MR-130A-01) that delivers a progestin-only hormone through the skin. About 1630 healthy women of childbearing potential will use the patch for 13 cycles to see how well it prevents pregnancy and how safe it is. The study is…
Phase: PHASE3 • Sponsor: Mylan Pharmaceuticals Inc • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC